Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-4673
Fax+1 214-645-2542
Dr. Hammers is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2005 - 2009- Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 2002 - 2005
Certifications & Licensure
TX State Medical License 2016 - 2026
MD State Medical License 2009 - 2022
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Start of enrollment: 2015 Mar 28
- SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients Start of enrollment: 2017 Mar 01
Publications & Presentations
PubMed
- Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.Toni K Choueiri, Robert J Motzer, Jose A Karam, Wesley Yip, Cristina Suárez
The New England Journal of Medicine. 2026-07-02 - The seventh kidney cancer research summit: progress in accelerating cures.Toni K Choueiri, A Ari Hakimi, Rana McKay, Sumanta K Pal, Thomas Powles
The Oncologist. 2026-06-06 - Differential Tumor Response Patterns and Extent of Necrosis After Immunotherapy Combinations Predict Clinical Responses for Renal Cell Carcinoma.Wadih Issa, Nicolas Sayegh, Damla Gunenc, Navneet Kaur, Andrew DeVilbiss
Clinical Genitourinary Cancer. 2026-06-01
Press Mentions
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease ControlNovember 11th, 2024- National Cancer Institute Renews $11.5 Million Program of Excellence Award in Kidney CancerSeptember 19th, 2022
UT Southwestern Develops Test to Predict Immunotherapy Response in Kidney CancerJune 4th, 2019
Professional Memberships
- Member
- Member
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
